Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldafermin PK in Impaired Renal Function
NCT04179630Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldafermin in Nonalcoholic steatohepatitis (NASH), sponsored by NGM Biopharmaceuticals. Primary endpoints: Maximum observed plasma concentration of aldafermin at Day 4 and Area under the concentration-time curve extrapolated to infinity at Day 4. Started Nov 2019; status: completed.
02
Drugs
aldafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04179630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179630.